GSK Acquires Efruxifermin for $2B, Targeting MASH and Liver Fibrosis

Published on Spencer Knight via LinkedIn

GSK is acquiring efruxifermin alfa from Boston Pharmaceuticals for up to $2 billion, including $1.2 billion upfront and $800 million in milestone payments. The FGF21 analogue therapy, originally developed by Novartis, targets metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease (ALD).

Phase 2 data showed significant reversal of liver fibrosis, improvements in glucose and triglycerides, and strong tolerability. The once-monthly injectable will now join GSK’s internal pipeline alongside GSK532990, an investigational siRNA for liver conditions. Commercial launch is expected by 2029.

Read the full post on LinkedIn:

👉 Spencer Knight: GSK makes $2B Liver Disease Acquisition

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.